16 November 2023
16 November 2023
Clinical Trials Arena explores how post-marketing studies are still led by academia while commercial sponsors spearhead early clinical research.
Certa plans to discuss trial plans with the FDA in early 2024, with the trial set to begin later in the year.
Amyl Therapeutics claims that its candidate has an advantage over monoclonal amyloid drugs as it targets all amyloid folds.
The non-invasive Vivally device uses neuromodulation to block electric signals along nerves to the brain that encode urinary urges.
The trial’s topline results are expected to be revealed by the end of December.
The company plans to enrol nearly 95 subjects at various trial sites in the US.
The trial will enrol subjects with various types of recurrent or refractory solid tumours.
The trial is currently enrolling participants in the UK, Canada and Australia.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
